Tuesday, September 1, 2026

Characteristics and Monitoring of the 2026 #Outbreak of #Ebola Disease Caused by #Bundibugyo Virus — #DRC, August 2026 (MMWR, edited)

 


Summary

    ° What is already known about this topic?

        § In May 2026, an outbreak of Ebola disease caused by Bundibugyo virus was identified in the Democratic Republic of the Congo.

    ° What is added by this report?

        § This ongoing outbreak is now the second largest Ebola outbreak in history. The targets for five critical public health response indicators (case detection alerts, contact tracing, laboratory testing, isolation of infected persons, and safe and dignified burials) have not yet been met, and the outbreak continues to expand rapidly.

    ° What are the implications for public health practice?

        § Substantial improvements in established outbreak control measures are crucial to rapidly detect and diagnose cases and isolate and provide treatment for infected persons, prevent funeral-associated transmission to prevent additional spread, and control this rapidly expanding outbreak.



    The Democratic Republic of the Congo (DRC) Ministry of Public Health declared an Ebola outbreak on May 15, 2026. Two days later, CDC activated its Emergency Operations Center as part of the U.S. government response to this rapidly growing outbreak. This report describes the epidemiologic characteristics and monitoring of the ongoing outbreak in DRC.


Investigation and Outcomes

Background

    The 2026 Ebola DRC outbreak caused by Bundibugyo virus is now the second largest Ebola outbreak ever recorded. As of August 21, 2026, DRC reported 5,458 confirmed cases and 2,606 (48%) confirmed deaths

    Compared with previous Ebola outbreaks, the increase in cases in DRC is unprecedented, with approximately 5,000 cases in 100 days (Ebola Outbreak: Current Situation | CDC). 

    Cases have been reported from six of the 26 DRC provinces (Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshop), affecting 57 of 151 health zones in the affected provinces. 

    Ituri province remains the outbreak epicenter, accounting for 84% of reported cases. 

    Strategies known to control Ebola outbreaks include community-based surveillance, case detection alert notifications,* rapid and in-depth case investigations, identification and monitoring of contacts, infection control measures (e.g., prompt isolation of persons with suspected or confirmed Bundibugyo virus disease [BVD]), rapid diagnostic testing, mortality surveillance, and safe and dignified burials (SDBs).†


Data Source

    Operational indicators for five domains have been generated based on experience with previous Ebola outbreaks, including DRC’s 2018 outbreak. Targets reflect the levels necessary to end the outbreak. 

    The DRC Ministry of Public Health prepares publicly available daily situation reports, and CDC abstracts data from these reports to evaluate the established indicators each day. Indicator data are monitored over time to assess the outbreak trajectory. This activity was reviewed by CDC, deemed not research, and conducted consistent with applicable federal law and CDC policy.§


Operational Indicator Analysis

    Nearly all operational indicators remain below identified targets (...). 

    Operational indicator values were calculated for the 21-day period of July 31–August 21. 

    The average percentage of alerts investigated within 24 hours (last reported August 5, 2026) was 83% (target = >90%). 

    An average of 10.6 contacts were identified per confirmed case (target = ≥20), suggesting underreporting and underascertainment of case contacts. 

    The percentage of confirmed new cases previously identified as known contacts (last reported July 12, 2026) was 15%–20% (target = >90%); this suggests that most cases are occurring outside known transmission chains

    In addition, more than one half (59%) of confirmed Ebola deaths are occurring outside an Ebola treatment unit (ETU) (target = 0%), suggesting insufficient ETU capacity, fear of ETUs, and ongoing spread through unidentified transmission chains. 

    Laboratory testing was performed for 72% of validated alerts (target = >90%), indicating that a substantial number of suspected cases remain untested. 

    Test positivity was 24%, with a target of 0%. 

    Although the national ETU bed occupancy was 64%, meeting the target of <80%, occupancy varied substantially by health zone, with some facilities unable to isolate all infected persons and reporting occupancies as high as 140%. 

    Fewer than one half (49%) of affected health zones had at least one SDB team (target = 100%). 

    Current data were not available for several response indicators, such as percentage of persons with confirmed BVD receiving prompt isolation (target = >90%) and percentage of deaths with SDBs (target = 100%), underscoring ongoing data gaps in this complex public health response.


Preliminary Conclusions and Actions

    As of August 21, 2026, most operational indicator measures remained below established response targets, and data for others were unavailable, indicating gaps in surveillance, contact tracing, laboratory testing, health care–seeking, isolation, and SDB capacity that limit control of the ongoing outbreak. 

    These missing data and operational gaps, together with continued geographic expansion of the outbreak, a high percentage of deaths occurring outside ETUs, and a low percentage of cases among persons previously identified as contacts, indicate uncontrolled expansion of the outbreak

    Public health response activities are complicated by a protracted complex humanitarian emergency in the eastern part of DRC, including armed conflict, limited health infrastructure, population displacement and mobility, and constraints on access to affected communities.

    Containment and control of the 2026 Ebola disease outbreak requires integration and coordination of at least five response areas: 

    1) expansion of community-based surveillance systems ensuring rapid investigation of alerts; 

    2) improvements in contact tracing completeness and timeliness; 

    3) expansion of treatment and isolation capacity in affected health zones; 

    4) increased laboratory testing capacity, enabling prompt case identification; and 

    5) ensuring SDBs in affected health zones.

    

    In addition, collecting robust, high-quality data regarding these operational actions is essential at the health zone level; CDC’s continued support to the DRC Ministry of Public Health and partners with improving data collection is critical. 

    Collecting data at the level of the health zone facilitates timely local outbreak response decisions. 

    Rapidly enhancing international humanitarian coordination and mobilizing global technical, operational, and other needed support are critical for accelerating the response and controlling the outbreak.


CDC 2026 Ebola Response International Epidemiology and Laboratory Task Force

Christine Atherstone, Amy Boore, Vance Brown, Jonathan Bryant-Genevier, Nirma Bustamante, Maestro Evans, James Fuller, Timothee Kinkela, John D. Klena, Thomas C. McHale, Elissa Meites, Emmanuel A. Mensah, Mpingulu Minlangu, Pierre Muhoza, Mike Park, Jaymin Patel, Satish K. Pillai, Anne Purfield, Logan Ray, Jessica N. Ricaldi, Katrin S. Sadigh, Dean Sayre, Trevor Shoemaker, Rachel Snyder, Christina Spiropoulou, Leisel Talley, Alison Todres, Sebastien Tshipamba, Amy Whitesell, Hailey Whitmire, Kristina Wielgosz, Emily Zielinski-Gutierrez, CDC; Democratic Republic of the Congo, Ministry of Public Health.

Corresponding author: Sascha Ellington, frk5@cdc.gov.

Source: 


Link: http://dx.doi.org/10.15585/mmwr.mm7535e1

____

#Genome-informed structural #analysis of #polymerase and glycoprotein #adaptation in #H5N1 clade 2.3.4.4b

 


Abstract

Importance

Understanding the molecular mechanisms driving H5N1 clade 2.3.4.4b is critical for pandemic preparedness.

Objective

To characterize the molecular drivers of viral fitness and mammalian adaptability in recent H5N1 viruses by integrating evolutionary dynamics with structural simulations.

Methods

This study analyzed 2,398 H5Nx genomes (2000–2024) through phylogenetic and selective pressure analyses. HA/NA structures were predicted with AlphaFold 3 and evaluated by AutoDock4 docking, whereas polymerase–ANP32A/B complexes were modeled using template-based methods and their binding free energies were estimated using MM/GBSA. Polymerase–ANP32E complexes were predicted with AlphaFold 3 and similarly evaluated by MM/GBSA. The binding affinities (ΔG) for the sialic acid (SA) receptors and human ANP32 proteins were quantified through molecular mechanics/generalized born surface area calculations.

Results

Clade 2.3.4.4b showed significant antigenic drift in the HA receptor binding site, reducing affinity for α2,3-SA and α2,6-SA receptors. On the other hand, the emergence of a full-length stalk N1 NA with second sialic acid-binding site mutations (e.g., N366S) compensated for reduced HA affinity by enhancing the NA binding stability. In the polymerase complex, both the PB2-627E/631L variant (−144.00 kcal/mol; unadjusted p = 0.0058) and the known mammalian-adaptive 627K/631M variant (−144.67 kcal/mol; unadjusted p = 0.0165) showed more favorable predicted human ANP32B binding free energies than the ancestral 627E/631M state (−136.46 kcal/mol).

Conclusions and Relevance

The co-occurrence of HA, NA, PB1, and PB2 signatures was associated with clade expansion and produced structural predictions consistent with altered receptor or ANP32 interactions; experimental validation is required before inferring effects on fitness or zoonotic risk.

Source: 


Link: https://vetsci.org/DOIx.php?id=10.4142/jvs.26088

____

Avian #Influenza #Report: August 23 - 29 '26 (Wk 35) (CHP, HK SAR September 1, 2026): 1 New #Human Infection with #H9N2 virus in Anhui, 20 cases so far this year


 

{Excerpt}

(...)

Avian influenza A(H9N2):

    ° Anhui Province {China}:

        § A three-year-old boy with onset on August 3, 2026.

(...)

Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/en/index.html

Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk35.pdf

____

The first high pathogenicity avian #influenza #H5N1 clade 2.3.4.4b incursions in Hunter New England region, NSW, #Australia, June–July 2026

 


Abstract

Two incursions of high pathogenicity avian influenza (HPAI) A(H5N1) clade 2.3.4.4b in vagrant birds were identified in the Hunter New England region of New South Wales, Australia on 28 June 2026 and 10 July 2026. These were the first detections of the virus in New South Wales and occurred shortly after the first Australian detection in June 2026. The Hunter New England Population Health Unit managed human contacts of the infected birds using a contact management system designed and purpose-built by the Unit. We report on the public health response and opportunities for improvement.

Source: 


Link: https://ojs.cdi.cdc.gov.au/index.php/cdi/article/view/3492

____

#Report on #influenza viruses received and tested by the #Melbourne #WHO Collaborating Centre for Reference and Research on Influenza during 2025

 


Abstract

As part of its role in the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne (the Centre) received 13,817 human influenza-positive samples during 2025. Viruses were analysed for their antigenic, genetic, and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hens’ eggs for potential use in seasonal influenza virus vaccines. Of the 13,817 samples received or processed, influenza A(H1N1)pdm09 viruses predominated, accounting for 46.1% of samples, compared to 21.2% for A(H3N2) viruses and 19.5% for influenza B viruses; one influenza C virus was received. Among viruses analysed at the Centre, the majority of A(H1N1)pdm09 (> 99%) and influenza B (98%) viruses were antigenically similar to their respective WHO recommended vaccine strains for the Southern Hemisphere in 2025. In contrast, only 43% of A(H3N2) viruses were antigenically similar to their respective WHO recommended vaccine strains. Of 3,307 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, 37 A(H1N1)pdm09 viruses showed highly reduced inhibition by oseltamivir and no influenza viruses tested showed highly reduced inhibition by zanamivir. Of 5,080 samples with sequencing of the polymerase acidic (PA) gene, no genetic markers associated with highly reduced susceptibility to baloxavir marboxil were identified.

Source: 


Link: https://ojs.cdi.cdc.gov.au/index.php/cdi/article/view/3489

____

#Nirmatrelvir–ritonavir targeting viral #persistence in post-COVID-19 condition (long #COVID) in the #USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial

 


Summary

Background

Post-acute sequelae of SARS-CoV-2 infection, more commonly known as long COVID, has emerged as a major health problem. The pathogenesis of long COVID is unknown, but among the leading hypotheses is viral persistence. We aimed to investigate whether the use of the SARS-CoV-2 antiviral nirmatrelvir–ritonavir improved long COVID symptoms.

Methods

We conducted a double-blind, placebo-controlled, randomised trial involving adults who had developed persistent symptoms (≥12 weeks) associated with three major symptom phenotypes (cognitive, autonomic, or exercise) after acute SARS-CoV-2 infection at 69 US sites. Participants were eligible if they were 18 years or older and had a previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization. Eligible participants were also required to have either at least two moderate symptoms from the same phenotype or one severe phenotype-associated symptom, as identified with the Cluster Targeted COVID-19 Symptom Questions. Participants were randomly allocated in a double-blind manner in a 1:1:1 ratio using permuted blocks of size 30 to receive either 15 days of active intervention followed by 10 days of placebo (300 mg nirmatrelvir–100 mg ritonavir twice daily, then 100 mg ritonavir–placebo); 25 days of active intervention (300 mg nirmatrelvir–100 mg ritonavir twice daily); or 25 days of placebo–ritonavir (100 mg ritonavir–placebo). A clinically significant change in patient-reported outcomes at day 90 comprised the primary endpoint: Patient-Reported Outcomes Measurement Information System Cognitive Function Short Form 8a, Orthostatic Hypotension Questionnaire question 1, and a modified version of the DePaul Symptom Questionnaire Post-Exertional Malaise short form. Secondary outcomes were phenotype-specific performance measures. The study was registered at ClinicalTrials.gov (NCT05595369) and is complete.

Findings

Between July 27, 2023, and Sept 6, 2024, 1207 individuals were screened. Of these, 964 were randomly allocated and 959 participants, excluding four participants who were later found ineligible and one who did not initiate treatment, were enrolled in the three phenotypes: 332 to cognitive, 334 to autonomic, and 332 to exercise. In the 959 participants in the mITT population, 643 (67%) self-reported as female, 314 (33%) were male, and two participants had a sex of unknown or undifferentiated; 750 (78%) were White; and 108 (11%) were Hispanic, Latino, or Spanish. The median age was 49 years (IQR 38–59). No statistically significant benefits were observed for any phenotype for primary endpoints. For the cognitive phenotype, adjusted differences compared to placebo were 3·2% (95% CI –10·4 to 16·8, p=0·65) for the 25-day regimen and –2·2% (–15·5 to 11·1, p=0·74) for the 15-day regimen. For the autonomic phenotype, adjusted differences were –6·4% (–18·5 to 5·7, p=0·30) for the 25-day regimen compared to placebo and –0·1% (–12·5 to 12·3, p=0·99) for the 15-day regimen compared to placebo. For exercise, adjusted differences were –7·8% (–19·5 to 3·8, p=0·19) for the 25-day regimen compared to placebo and 0·9% (–11·4 to 13·2, p=0·88) for the 15-day regimen compared to placebo. There were no differences in secondary endpoints, and no safety signals were observed; there were no deaths, and 52 serious adverse events occurred in 42 (4%) of 963 participants over the course of the study.

Interpretation

Nirmatrelvir–ritonavir for 15 days or 25 days showed no evidence of benefit in long COVID in any of the three phenotypes studied. These findings suggest additional approaches to measuring the symptom burden and treating Long COVID are needed.

Funding

National Institutes of Health.

Source: 


Link: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00406-8/fulltext

____

#Bundibugyo at the #Border: The 2026 #Ebola #Outbreak and the Case for Pre-emptive #Countermeasure #Equity

 


Abstract

The 2026 Ebola outbreak caused by Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda exposes a persistent structural flaw in global health security: preparedness remains overwhelmingly reactive and pathogen-specific. Despite the $518 million Africa CDC-WHO joint continental plan, no licensed BDBV vaccine or therapeutic is available; a 21-day (three-week) detection delay and cross-border transmission expose inadequate inter-epidemic investment in non-Zaire ebolavirus countermeasures. We argue for sustained, ring-fenced financing, institutionalised cross-border coordination, species-inclusive diagnostics, and real-time genomic data sharing to move African Ebola preparedness from reactive to pre-emptive.

Source: 


Link: https://www.sciencedirect.com/science/article/pii/S1477893926000682?via%3Dihub

____

#Taiwan, Seasonal #Influenza and #COVID19 Epidemics Situation #Update (CDC, September 1 '26): #H1N1pdm09 flu virus and PQ.16.1.1 SARS-CoV variant are predominant

 


{Excerpt}

(...)

    The CDC pointed out that in the 34th week (August 23-29), there were 101,628 outpatient and emergency room visits for influenza-like illnesses, an increase of 5.6% compared to the previous week, showing a recent slow upward trend. 

    In addition, last week (August 25-31), there were 85 new cases of severe influenza complications (80 H1N1, 3 H3N2, and 2 untyped A cases) and 14 deaths (12 H1N1, 1 H3N2, and 1 untyped A case). 

    Laboratory monitoring data shows that the influenza virus currently circulating in the community is mainly type A, with type A H1N1 accounting for 74.1% of the cases

    This flu season (2023-2024) has seen a cumulative total of 1,224 severe cases (620 H1N1, 494 H3N2, 20 untyped type A, and 90 type B) and 234 deaths (113 H1N1, 102 H3N2, 7 untyped type A, and 12 type B). 

    The majority of severe cases are among those aged 65 and above (64.6%) and those with a history of chronic diseases (82.8%). 69.4% of those affected have not received the flu vaccine this season.


    According to data from the Taiwan Centers for Disease Control (CDC), the COVID-19 epidemic in Taiwan is declining, but it remains at a plateau. 

    In the 34th week (August 23-29), there were 21,969 outpatient and emergency room visits related to COVID-19, a 13.4% decrease compared to the previous week (August 16-22). 

    Last week (August 25-31), there were 69 new locally transmitted severe cases and 18 local deaths

    Since October 2025, there have been a cumulative total of 549 locally transmitted cases of COVID-19 complicated by severe illness, of which 91 have died

    The majority of severe cases are among those aged 65 and above (72.5%) and those with a history of chronic diseases (83.1%). 85.1% of these cases have not received the COVID-19 vaccine this season. 

    In the past four weeks, the predominant variant strain in locally transmitted cases has been PQ.16.1.1.

(...)

Source: 


Link: https://www.cdc.gov.tw/Bulletin/Detail/GWRkQ03fZuKKWwdv191UyQ?typeid=9

____

Monday, August 31, 2026

#Antibody profiles across #H5N1 and previously circulating viruses are highly dynamic and #age- and imprint- independent

 


Abstract

The increasing incidence of H5N1 influenza virus transmission from animal species to humans has heightened concerns about an imminent H5N1 pandemic. Prior studies using recombinant hemagglutinin and neuraminidase proteins have reported age-dependent cross-reactivity to H5N1, attributed to immune imprinting from an individual's first influenza virus exposure. However, whether this pattern holds when using whole inactivated virus (WIV), capturing antibodies against diverse viral proteins, and is stable over time remains unknown. We therefore aimed to determine whether H5N1 cross-reactivity of pre-existing antibodies to whole virus follows an age-dependent or imprinting-specific pattern, and whether this pattern is stable over a five-year period. To this end, we measured serum antibody levels in adolescents, adults and seniors by ELISA using whole inactivated H5N1 virus as antigen rather than purified proteins. Detectable, albeit generally low, levels of H5N1-reactive antibodies were present in most individuals, irrespective of age. Comparison of antibody levels against H5N1 with those to five historical influenza virus strains revealed a consistent positive correlation between H5N1-reactive antibodies and responses to the H1N1pdm09 strain A/California/7/2009 (CA), across all age groups. Using unbiased clustering of antibody titers against H5N1, CA, and the H3N2 strain A/Perth/16/2009 (PE), we identified seven distinct age-transcending antibody profiles. These profiles covered individuals with varying titers to all three included viruses but also identified individuals with high anti-CA levels, yet low anti-H5N1 levels and vice versa. Moreover, despite stable antibody levels over a five-year interval in the study population, individual antibody levels and profiles fluctuated considerably over this period. Taken together, our results confirm the presence of H5N1-reactive antibodies in human sera and their association with previously circulating strains. However, they also caution against inferring antibody levels against a new strain based solely on responses to antigenically related strains and highlight the limitations of extrapolating immune status from single timepoint measurements.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.08.26.26361396v1

____

Acute #Protein Responses Control #SARS-CoV-2-specific #Neurocognitive and General Post-Viral #Sequelae

 


Abstract

Post-acute infection syndromes (PAIS) follow viral syndromes including post-acute sequelae of COVID19 (PASC) which complicates 10-25% of SARS-CoV-2 infections. These syndromes lack precise explanatory mechanisms. We studied 173 human saliva proteomes during respiratory viral syndromes, seeking associations between 44 clinically-relevant protein expression patterns and subsequent sequelae counts. Exploratory models adjusted by extensive clinical annotations found interactions between 23 acutely-responsive proteins and SARS-CoV-2 infection that inversely predicted subsequent neurocognitive sequelae. An overlapping 19 acutely-responsive proteins during any acute respiratory viral syndrome inversely predicted general fatigue-related sequelae. Altogether, 29 proteins, derived from interferon stimulated genes (ISG), were uniformly beneficial, including 13 predictive of both neurocognitive and general sequelae. The proteins suggested both shared early pathobiology and virus-specific protective responses that shaped resolution of acute disease and different PAIS. Acutely elevated protective ISG proteins associated with reduced post-viral symptoms identify investigational starting points for novel mechanisms, diagnostics and therapeutics for PASC and PAIS.


Competing Interest Statement

Theodore G. Liou, Judy L Jensen and Kristyn A Packer received research funding from Anagram, Aridis, BioMX, Calithera, Clarametyx, Gilead, Insmed, Laurent, Novartis, the US Cystic Fibrosis Foundation′s Therapeutic Development Network and Vertex for performance of clinical studies during the study period. Bricelyn H Strauch maintains the copyright for Figure 3. Theodore Liou and Frederick Adler, through the University of Utah, are named as inventors on the following patent applications related to the proteins identified in this manuscript: (1) a provisional patent application titled ″DIAGNOSTICS AND TREATMENTS FOR ACUTE AND POST-VIRAL DISEASE BASED ON INNATE IMMUNE RESPONSES TO SARS-COV-2 INFECTION,″ serial number 63/792,687, filed 4/22/2025; (2) a provisional patent application titled ″ADDITIONAL INNATE IMMUNE RESPONSES WITH DIAGNOSTIC AND TREATMENT POTENTIAL FOR POST-ACUTE SEQUELAE OF COVID19 SYNDROME AND FOR POST-ACUTE INFECTION SYNDROME,″ serial number 63/979,883, filed 2/10/2026; (3) a Patent Cooperation Treaty (PCT) application titled ″METHODS FOR PREDICTING POST-ACUTE SEQUELAE OF VIRAL INFECTIONS USING INTERFERON STIMULATED GENE PROTEINS,″ serial number PCT/US2026/024520, filed 4/21/2026, which incorporates subject matter from (1) and (2); and (4) a provisional patent application titled ″ADDITIONAL ACUTELY EXPRESSED PROTEINS PROTECTIVE AGAINST NEUROCOGNITIVE AND GENERAL POST-VIRAL SEQUELAE,″ serial number 64/102,461, filed 6/30/2026. The applicant on all applications is the University of Utah.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.08.27.26361488v1

____

#Immunity Interrupted: Links Between #SARS-CoV-2 and the #Tripledemic of 2022

 


Highlights

    • SARS-CoV-2 infection was associated with fewer subsequent respiratory viral infections in children.

    • Children with prior SARS-CoV-2 infection had a longer interval before reinfection than those with other respiratory viral illnesses.

    • Rates of respiratory viral coinfection were lower following SARS-CoV-2 infection compared with other viral infections.

    • Prior SARS-CoV-2 infection was not associated with increased susceptibility to recurrent respiratory viral infections.

    • Findings support a potential role for viral interference and post-infection immune modulation in respiratory virus dynamics.


Abstract

Background

The post-pandemic resurgence of respiratory viral infections, commonly referred to as the "tripledemic," raised concerns that prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may increase susceptibility to subsequent respiratory illnesses. However, the relationship between SARS-CoV-2 infection and future respiratory viral infections in children remains poorly understood.

Objectives

To determine whether pediatric patients with SARS-CoV-2 infection were at increased risk of subsequent respiratory viral infections within 120 days compared with children diagnosed with other respiratory viral infections and to evaluate coinfection frequency and clinical outcomes.

Study Design

We conducted a retrospective cohort study of pediatric patients aged 6 months to <18 years presenting to emergency departments within a large healthcare system between January 1, 2021, and December 31, 2023. Patients were categorized as SARS-CoV-2 only (n=4,004), SARS-CoV-2 with respiratory viral coinfection (n=1,678), or other respiratory viral infection only (n=31,434). Patients were followed for 120 days after the index encounter. Primary outcomes included subsequent respiratory viral infections and laboratory-confirmed reinfections. Secondary outcomes included coinfection rates, oxygen supplementation, mechanical ventilation, and hospital length of stay.

Results

A total of 37,116 pediatric patients met inclusion criteria. Subsequent respiratory viral infections occurred less frequently among patients with SARS-CoV-2-only infection (4.4%) compared with patients with SARS-CoV-2 coinfection (6.0%; OR 1.39, 95% CI 1.08–1.79) and those with other respiratory viral infections (6.1%; OR 1.43, 95% CI 1.22–1.68). The mean time to subsequent infection was longest in the SARS-CoV-2-only group (68.4 days) compared with the SARS-CoV-2 coinfection (60.8 days) and other viral infection groups (58.8 days). Laboratory-confirmed reinfections occurred in 2.0% of patients with SARS-CoV-2-only infection and 2.8% of patients in both comparison groups. Coinfections were less common among patients with SARS-CoV-2 infection than among those with other respiratory viral infections. Severe clinical outcomes were uncommon across all groups. Although patients with SARS-CoV-2-only infection had slightly longer hospital stays and higher rates of mechanical ventilation, absolute event rates remained low.

Conclusions

Prior SARS-CoV-2 infection was not associated with an increased risk of subsequent respiratory viral infections in children. Instead, SARS-CoV-2 infection was associated with fewer subsequent infections, lower coinfection rates, and a longer interval before reinfection compared with other respiratory viral illnesses. These findings support the possibility of viral interference or transient immune-mediated protection following SARS-CoV-2 infection and suggest that factors other than prior SARS-CoV-2 infection were more likely responsible for the increased burden of respiratory viral illnesses observed during the post-pandemic period.

Source: 


Link: https://www.sciencedirect.com/science/article/abs/pii/S1386653226000855?dgcid=rss_sd_all

____

Isolation and characterisation of #Nipah virus neutralising candidate therapeutic monoclonal #antibodies from an #mRNA-immunised pig

 


Abstract

Nipah virus (NiV) is a highly pathogenic zoonotic paramyxovirus with epidemic potential. Despite the threat NiV poses, no therapeutics are licensed to treat infection. Studies have shown that monoclonal antibodies (mAb) can protect animals against NiV and the related Hendra virus (HeV). The best studied mAb, m102.4, has been used to treat infected patients on a compassionate basis, and has entered clinical trials. However, there is a need to define additional mAbs with therapeutic potential, which could be combined with m102.4 to improve neutralising potency and breadth. Here, we isolated five high affinity mAbs from an mRNA immunised pig, which bound the G glycoprotein derived from NiV Malaysia strain (NiV-M), and one of which (mAb A2) also bound HeV G. Aligned with this, all mAbs neutralised NiV-M pseudovirus but only mAb A2 neutralised pseudovirus representing the NiV Bangladesh (NiV-B) strain. mAb A2 and the most potent NiV-M neutralising mAb, C1, showed minimal competition with each other and m102.4, suggesting recognition of non-overlapping epitopes. Single-particle cryogenic electron microscopy of the NiV-M G receptor binding domain complexed to A1 and C2 Fab fragments revealed distinct epitopes that did not overlap with the receptor-binding site, targeted by m102.4, suggesting action through steric impedance of receptor binding or interference downstream of receptor engagement. Inoculation of mAb A2 to hamsters did not provide complete protection against NiV-B challenge (60% survival), however, a split dose of mAb A2 and m102.4 provided the same protection as m102.4 alone (100% survival). Collectively, these data demonstrate the potential of the porcine model for isolation of therapeutic candidate mAbs, which contribute both to our understanding of the NiV G antigenic landscape, and the development of mAb combinations, that exert complementary mechanisms of neutralisation, for therapeutic intervention.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

European Commission, https://ror.org/00k4n6c32, VetBioNet, EMJMD LIVE

Innovate UK, 971555

UK Research and Innovation, BBS/E/I/00007031, BBS/E/I/00007037, BBS/E/I/00007038, BBS/E/I/00007039, MR/S007555/1, BB/T008784/1

Wellcome Trust, 203141/Z/16/Z

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.08.28.745669v1?rss=1

____

Sunday, August 30, 2026

Landscape with a Footbridge, Albrecht Altdorfer (1518)

 


{Click on Image to Enlarge}

___

Public Domain.

Source: 


Link: https://www.wikiart.org/en/albrecht-altdorfer/landscape-with-a-footbridge

____

#Influenza A virus #H5N1 genotypes #B3.13 and D1.1 show #temperature-dependent restriction of #replication in primary #human respiratory epithelial cell cultures derived from the upper and lower respiratory tract

 


Abstract

H5N1 clade 2.3.4.4b avian influenza A viruses pose a significant threat to wild animal populations, domesticated animals, and potentially, the human population. For H5N1s to infect and transmit among mammalian species, mutations for improved utilization of mammalian receptors and enhanced replication at the lower temperatures of the upper respiratory tract need to be acquired. A human H1N1pdm09-like virus was compared to H5N1 genotypes B3.13 and D1.1 for replication at 33ºC, 37ºC, and 39ºC – temperatures consistent with the upper and lower respiratory tract in humans, and dairy cow udder tissue. All H5N1 viruses had increased plaque sizes on MDCK cells at 37ºC and 39ºC compared to H1N1pdm09. In primary, differentiated human nasal and bronchial epithelial cultures, all H5N1 viruses show restricted infectious virus production compared to H1N1 at 33ºC. While H5N1 D1.1 also showed restricted replication at 37ºC and 39ºC, the H5N1 B3.13 replicated to nearly equivalent titers as H1N1pdm09. All H5N1 viruses demonstrated similar cell tropism in cells from the upper and lower respiratory tract, infecting more ciliated than non-ciliated cells relative to H1N1pdm09. H1N1, H5N1 B3.13 D1.1 infection induced similar innate immune factors, with nasal epithelial cells producing higher levels compared to bronchial epithelial cells. These data suggest that genotype B3.13 and D1.1 H5N1 viruses show different temperature dependent replication patterns compared to H1N1pdm09.

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.08.27.747488v1

____

Saturday, August 29, 2026

History of Mass Transportation: The CP 0180 Steam Locomotive of Portuguese Railways

 


{Click on Image to Enlarge}

___

By Nelso Silva - CP 0186, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=50084760

Source: 


Link: https://en.wikipedia.org/wiki/Comboios_de_Portugal

____

#Coronavirus Disease Research #References (AMEDEO, August 29 '26)

 


    Antiviral Res

  1. PU F, Guo Y, Pan X, Liu X, et al
    Dual-targeting engineered binding proteins block SARS-CoV-2 infection and complement activation.
    Antiviral Res. 2026;254:106515.
    PubMed         Abstract available


    Clin Infect Dis

  2. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
    Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI.
    Clin Infect Dis. 2025 Dec 19:ciaf460. doi: 10.1093.
    PubMed        

  3. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
    Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI.
    Clin Infect Dis. 2025 Dec 19:ciaf461. doi: 10.1093.
    PubMed        


    Infect Control Hosp Epidemiol

  4. PRAKASH-ASRANI R, Shioda K, Bower CW, Steinberg JP, et al
    Impact of hand hygiene on the detection of multidrug-resistant organisms and other pathogens of epidemiologic significance after implementation of an automated hand hygiene monitoring system.
    Infect Control Hosp Epidemiol. 2026 Aug 27:1-7. doi: 10.1017/ice.2026.10524.
    PubMed         Abstract available


    Int J Infect Dis

  5. WAGATSUMA K, Song Z, Lam TTY, Kwok KO, et al
    Changes in respiratory virus seasonality across the COVID-19 pandemic: a multicentre comparative study in Leicester, Rotterdam, Hong Kong, and Christchurch.
    Int J Infect Dis. 2026 Aug 27:109080. doi: 10.1016/j.ijid.2026.109080.
    PubMed         Abstract available

  6. RAGHUVAMSI PV, Loh SB, Bhattacharya P, Ho J, et al
    Investigating the effectiveness of multimodal data in forecasting SARS-COV-2 case surges.
    Int J Infect Dis. 2026 Aug 25:109062. doi: 10.1016/j.ijid.2026.109062.
    PubMed         Abstract available


    J Infect

  7. SANDERSON ND, Dingle KE, Hopkins KMV, Vaughan A, et al
    Clinical validation of an optimised metagenomic nanopore sequencing method for detecting viral respiratory pathogens.
    J Infect. 2026 Aug 22:106839. doi: 10.1016/j.jinf.2026.106839.
    PubMed         Abstract available


    J Med Virol

  8. LI J, Song W, Li J, Peng R, et al
    Enhanced Immunogenicity and Cross-Neutralizing Activity of a Trivalent Adenoviral Vector-Based SARS-CoV-2 Vaccine in Mice.
    J Med Virol. 2026;98:e71119.
    PubMed         Abstract available


    J Virol

  9. LIU G, Chen J, Wu F, Wei P, et al
    Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.
    J Virol. 2026 Aug 28:e0059926. doi: 10.1128/jvi.00599.
    PubMed         Abstract available

  10. STADLER E, Mordant F, Gartner M, Docken SS, et al
    Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays.
    J Virol. 2026 Aug 27:e0082326. doi: 10.1128/jvi.00823.
    PubMed         Abstract available

  11. DE BEIJER NL, Limpens RWAL, Barcena M, Snijder EJ, et al
    Conserved structural features of RNA export pores spanning the double membrane of arterivirus and coronavirus replication organelles.
    J Virol. 2026 Aug 26:e0085926. doi: 10.1128/jvi.00859.
    PubMed         Abstract available

  12. KUMAR S, Lai L, Ellis ML, Patel A, et al
    Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.
    J Virol. 2026 Aug 26:e0074926. doi: 10.1128/jvi.00749.
    PubMed         Abstract available


    JAMA

  13. CHUNG TH, Raj SR
    Postural Orthostatic Tachycardia Syndrome (POTS): A Review.
    JAMA. 2026 Aug 24. doi: 10.1001/jama.2026.14809.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 29 '26)

 


    BMC Pediatr

  1. ROHDE G, Haraldstad K, Helseth S, Hagen M, et al
    Health-related quality of life in parents of adolescents in 2019, 2021 and 2023.
    BMC Pediatr. 2026;26:783.
    PubMed         Abstract available

  2. ZHU L, Zeng L, Zhang M, Chen X, et al
    Comparison of human metapneumovirus and respiratory syncytial virus in children with acute lower respiratory infections in Wenzhou, China from 2021 to 2022: a retrospective study.
    BMC Pediatr. 2026;26:774.
    PubMed         Abstract available


    J Immunol

  3. DICK JK, Krishna VD, Hicks D, Sangala JA, et al
    ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2.
    J Immunol. 2026;215:vkag235.
    PubMed         Abstract available


    J Virol

  4. ALYMOVA IV, Mekonnen B, Wang D, Kamal RP, et al
    N-linked glycosylation sites with low occupancy support sustained circulation of the A(H3N2) influenza A virus in the human population.
    J Virol. 2026 Aug 28:e0066226. doi: 10.1128/jvi.00662.
    PubMed         Abstract available

  5. BARRE RS, Nath H, Nogales A, Abdelwhab EM, et al
    NS-segment-based reporter influenza A viruses: engineering strategy, applications, and limitations.
    J Virol. 2026 Aug 26:e0109926. doi: 10.1128/jvi.01099.
    PubMed         Abstract available


    PLoS Comput Biol

  6. KENNEDY J, Ferguson W, Jones O, Riley S, et al
    Evaluation of short-term multi-target respiratory forecasts over winter 2024-25 in England using sub-ensemble contribution analyses.
    PLoS Comput Biol. 2026;22:e1014644.
    PubMed         Abstract available

  7. OSTHUS D, Murph AC, Goldberg EE, Beesley LJ, et al
    Leveraging synthetic and genetic data to improve epidemic forecasting.
    PLoS Comput Biol. 2026;22:e1014630.
    PubMed         Abstract available


    PLoS One

  8. HO QM, Duong BT, Nguyen LNT, Susilawati TN, et al
    ICU admission and mortality in adult patients with influenza A(H1N1)pdm09-related pneumonia in Vietnam since the 2009 H1N1 pandemic: A 10-year cohort study.
    PLoS One. 2026;21:e0348450.
    PubMed         Abstract available

  9. NASH RK, Bhatia S, Wardle J, Cori A, et al
    Forecasting COVID-19 cases in US states using reconstructed incidence data.
    PLoS One. 2026;21:e0353983.
    PubMed         Abstract available

  10. ARTEMCHUK O, Chakhunashvili G, Finci I, Rojas M, et al
    Factors associated with influenza vaccine uptake among healthcare workers in Georgia, 2021-2024.
    PLoS One. 2026;21:e0356495.
    PubMed         Abstract available

  11. MENDOZA-VELAZQUEZ A, Lara-Arevalo J, Mendoza-Martinez L, Drewnowski A, et al
    Rising food prices and widening nutrition gaps in Mexico: The cost of nutrient-dense and ultra-processed foods before, during, and after COVID-19.
    PLoS One. 2026;21:e0355198.
    PubMed         Abstract available

  12. OVERBOSCH FW, Waltz CNM, Cesuroglu T, Blokland B, et al
    Exploring integrated advice and avian influenza knowledge gaps by using a Highly Pathogenic Avian Influenza outbreak simulation.
    PLoS One. 2026;21:e0354920.
    PubMed         Abstract available

  13. SHARMA S, Elhassan H, Anderson KK, Heisel MJ, et al
    Changes in mental health outcomes of middle-aged and older adults during the COVID-19 pandemic: A scoping review.
    PLoS One. 2026;21:e0342140.
    PubMed         Abstract available

  14. EKHOLUENETALE M
    Decomposing socioeconomic inequalities in COVID-19 vaccination uptake among Nigerian women of reproductive age: A further analysis of population-based data.
    PLoS One. 2026;21:e0357171.
    PubMed         Abstract available

  15. PUEBLA G, Ferrer-Urbina R, Perez-Zapata D, Alarcon-Castillo K, et al
    Cognitive load and individual differences as drivers of health-related misinformation: A signal detection approach.
    PLoS One. 2026;21:e0356642.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  16. RIUMINA ED, Alekseeva EI, Klink GV, Feigin S, et al
    HLA class I escape drives the evolution of SARS-CoV-2 in human populations.
    Proc Natl Acad Sci U S A. 2026;123:e2619192123.
    PubMed         Abstract available

  17. LIU Q, Chen P, He C, Qiu Z, et al
    SESN1 is a negative regulator of MAVS and dynamically expressed during RNA viral infection.
    Proc Natl Acad Sci U S A. 2026;123:e2621443123.
    PubMed         Abstract available

  18. MONTGOMERIE I, McKenzie RE, Palmer OR, Mason NC, et al
    Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen.
    Proc Natl Acad Sci U S A. 2026;123:e2602574123.
    PubMed         Abstract available


    Vaccine

  19. KOONIN LM, Velez SD, Bresee JS
    Expanding adult immunization in low- and middle-income countries through pharmacist-provided vaccination.
    Vaccine. 2026;90:129004.
    PubMed         Abstract available

  20. KAZENZA B, Masokolo B, Mbunga B, Egbende L, et al
    Why COVID-19 vaccination struggled in the Democratic Republic of Congo: a qualitative study exploring organizational and sociocultural barriers, 2025.
    Vaccine. 2026;90:129033.
    PubMed         Abstract available

  21. HUIBERTS AJ, Eggink D, de Gier B, Karens T, et al
    Effectiveness of Omicron JN.1 vaccination against infection with JN.1-derived SARS-CoV-2 subvariants in a prospective cohort study in the Netherlands.
    Vaccine. 2026;90:129030.
    PubMed         Abstract available

  22. HUTTON DW, Prosser LA, Ortega-Sanchez IR, Leidner AJ, et al
    Evaluating the cost-effectiveness of respiratory syncytial virus vaccination among risk-stratified older adults.
    Vaccine. 2026;90:129023.
    PubMed         Abstract available

  23. PORTILHO AI, Andreata-Santos R, Duarte-Barbosa M, Chaves APC, et al
    Functional neutralizing and bactericidal antibody responses induced by dual-target immunization with SARS-CoV-2 RBD and Neisseria meningitidis antigens in mice.
    Vaccine. 2026;90:129011.
    PubMed         Abstract available

  24. AHI T, Andersen KM, Mateus JS, Yu T, et al
    2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults.
    Vaccine. 2026;90:129009.
    PubMed         Abstract available

  25. LIU X, Cloughesy JN, Yu T, Ferranna M, et al
    Uptake of the RSVpreF vaccine during pregnancy: associations with socioeconomic status, prenatal care utilization, and maternal risk factors.
    Vaccine. 2026;90:129003.
    PubMed         Abstract available

  26. KAZI F, Shapland CY, Spiga F, Villanueva G, et al
    Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant.
    Vaccine. 2026;90:128993.
    PubMed         Abstract available

  27. HUIBERTS AJ, Smits MMJ, Hoeve CE, de Melker HE, et al
    Association between post-vaccination adverse events and subsequent COVID-19 booster uptake in the Netherlands.
    Vaccine. 2026;90:129043.
    PubMed         Abstract available

  28. GENSOROWSKY D, Surmann B, Meyer AC, Poshtiban A, et al
    Corrigendum to "Outpatient care intensity and influenza vaccination: evidence from Germany" [Vaccine 70 (2026) 128038].
    Vaccine. 2026;90:129062.
    PubMed        

  29. BOTT L, Liu J, Challenger A, Powell E, et al
    Myth-busting influenza and fear of adverse reactions in healthcare workers: two experimental studies on vaccination intentions.
    Vaccine. 2026;91:129086.
    PubMed         Abstract available

2nd meeting of #IHR EC on #epidemic of #Ebola #Bundibugyo virus disease in #DRC – Meeting report (WHO, August 29 '26)



28 August 2026 | Statement | Geneva 


    The Director-General (DG) of the World Health Organization (WHO) is hereby transmitting the report of the second meeting of the International Health Regulations (2005) (IHR) Emergency Committee (Committee) regarding the epidemic of Ebola disease caused by Bundibugyo virus (BVD) in the Democratic Republic of the Congo (DRC), held on Tuesday, 18 August 2026, from 12:00 to 17:00 CEST.

    The DG welcomes the Statement by the Committee, presented at the beginning of its report, and expresses his most sincere gratitude to the Chair, Members, and Advisors of the Committee.

    Concurring with the advice expressed by the Committee during the meeting, the DG determined that the BVD epidemic in the DRC continues to meet the criteria of a public health emergency of international concern (PHEIC), but not those of a pandemic emergency. Accordingly, on 24 August 2026, the DG, considering the advice offered by the Committee, issued temporary recommendations to States Parties, available here.  

===


Statement by Committee

    The Committee commends the Government of Uganda for the rapid control of BVD transmission, with no new cases detected since 16 July 2026, and recognizes the major efforts being undertaken by the DRC, affected communities, WHO and national and international partners. Nevertheless, the Committee considers the continuing rapid growth and geographic expansion of the epidemic in the DRC to be of grave concern, requiring urgent, intensified and sustained action.

    As of 18 August 2026, approximately 5,000 BVD cases have been reported in the DRC. Available modelling suggests that substantial under-ascertainment may be occurring, with the true number of infections potentially three- to four-fold higher. Without a rapid change in the trajectory of transmission, the epidemic risks reaching a scale with profound national and regional consequences, with the potential for case numbers and deaths to exceed those seen in the 2013-2016 Ebola disease epidemic in West Africa. The Committee therefore emphasizes the need for urgent, decisive and coordinated action to control BVD transmission in the DRC.

    The BVD epidemic is occurring in the context of an already severe and complex humanitarian emergency. Areas with some of the highest BVD transmission burdens substantially overlap with areas affected by armed conflict, insecurity, population displacement and constrained humanitarian access.

    These conditions endanger affected populations and responders, impede community engagement, surveillance, contact tracing, safe and timely access to care, infection prevention and control (IPC), and other essential response operations.

    At the same time, disruption of essential health services risks increasing preventable deaths from malaria, diarrhoeal diseases, maternal causes and other conditions. Uncontrolled transmission also carries potentially serious consequences for neighbouring countries and for the social and economic stability of the Great Lakes region.

    The Committee emphasizes that communities must be at the center of the response. Erosion of trust in authorities and responders, insufficient community ownership, insecurity and operational and coordination weaknesses are major impediments to effective control. These challenges cannot be addressed through public health interventions alone. The response must be built with affected communities and supported by trusted local leaders and organizations, with transparent communication, meaningful participation and mechanisms through which community concerns rapidly influence response operations.

    The Committee notes that current epidemiological, clinical and genomic evidence does not indicate a fundamental change in the known biology, modes of transmission or clinical characteristics of Bundibugyo virus (BDBV). The priority, therefore, is to deliver science-based public health response interventions of proven effectiveness at sufficient speed, quality, coverage and scale.

    The Committee is deeply concerned that implementation of core essential public health response interventions has not yet consistently achieved the coverage and performance required to interrupt BVD transmission. 

    An immediate and drastic operational intensification and scale-up of response operations is required, potentially with an operational reset. 

    Particular priority needs to be given to: 

        - ensuring community engagement and community-based surveillance

        - rapid case detection, 

        - investigation and isolation; 

        - comprehensive contact identification and follow-up; 

        - IPC in BVD isolation and treatment centers, other health-care facilities and communities; 

        - safe and dignified management of deaths; 

        - timely laboratory diagnosis; and 

        - accessible, high-quality clinical care. 

    All these areas require intensification of efforts, and all should be viewed as essential components of an effective response. While none of these areas can afford to be neglected or deprioritized, the Committee identifies below specific areas requiring urgent action and particular focus.

    Effective vaccines and therapeutics against BVD, should they become available and be demonstrated to be safe and effective through rigorous clinical trials, could make an important contribution to reducing transmission, morbidity and mortality; however, they should complement rather than be a substitute for rigorous implementation of core public health measures.

    The response must be planned not only for the immediate term but for the sustained engagement that will be required over the coming months, or even years. This requires predictable financing, adequate human resources, secure access to communities, resilient supply chains, continuity of essential health services, and sustained national, regional and international political commitment.

    The Committee therefore calls for an immediate, unified and fully resourced intensification of the response, under the leadership of the Government of the DRC and with sustained regional and international support. The temporary recommendations issued by the DG should be translated into one integrated, time-bound and costed national action plan for the DRC, serving as the common framework for aligning the efforts and resources of the Government and national and international partners.

    The plan should establish clear responsibilities, measurable milestones and indicators; identify operational and geographic gaps; quantify the human, logistical and financial resources required; and include a companion gap analysis to guide urgent resource mobilization. Implementation should be reviewed frequently against agreed indicators and the evolving epidemiological situation, with rapid corrective action where milestones are not being achieved.

    Given the intersection between ongoing transmission, armed conflict, insecurity and restricted humanitarian access, the Committee emphasizes that high-level political engagement is urgently required to secure safe, sustained and unhindered access for epidemic-control operations that is being called for. 

    National, regional and international leaders should use all appropriate diplomatic and humanitarian channels to create the conditions necessary for effective implementation of comprehensive response measures. Where required, this should include arrangements for temporary cessations of hostilities or other humanitarian access measures that enable affected communities to receive essential health services and allow response teams to operate safely and effectively.

    The imperative is clear: interrupt BVD transmission rapidly, protect affected communities and health workers, maintain essential health services, prevent further geographic and cross-border spread, and mobilize the political, operational and financial support necessary to bring the epidemic under control.

    The Committee calls for particular focus on the following urgent priority interventions:

        § Drastic scale-up of trust-building and community engagement through trusted communication channels and local actors, including local leaders, religious leaders, traditional healers and survivors, to support community participation in fostering the acceptance of public health measures, including early detection, case referral, contact tracing, safe and dignified burial practices, and adoption of protective behaviours.

        § Drastic scale-up of IPC measures to prevent transmission in BVD isolation and treatment centers, other healthcare settings, and, in some circumstances, at home in the community. With regard to the latter, although it is not realistic to expect community members to be able to maintain the same level of application of IPC measures as in healthcare settings, it must be recognized that, for myriad reasons, many sick persons cannot or will not seek care in health care facilities. Until clinical care capacity can be augmented, along with the requisite enhanced security and community trust to motivate and permit sick persons to seek care, steps to limit transmission in the home, such as distribution of personal protective equipment, materials and disinfectants, may reduce transmission risk and morbidity, and may also represent a conduit for greater community engagement.

        § Drastic scale-up of BVD isolation and treatment centers staffed by a specifically trained workforce, with appropriate provision of personal protective equipment and materials.

        § In-depth analysis or research to identify and characterize BVD transmission dynamics associated with specific settings, including related modes of BVD transmission (e.g. caretaking in the home, hospital, or at traditional healers, re-use of needles). A better understanding of the epidemiology of the epidemic is essential for the implementation of effective interventions.

===

The Annex to this Report records the views of one Member of the Committee in relation to the “Statement by the Committee”.


===


Proceedings of the meeting

    All 12 Members of, and five Advisors to, the Committee participated in the meeting convened by teleconference, via Zoom, on Tuesday, 18 August 2026, from 12:00 to 17:00 CEST.

    The DG joined in person and welcomed the participants, including Government Officials designated to present their views to the Committee on behalf of the three invited States Parties – the DRC, France and Uganda. The opening remarks by the DG are available here.

    The Representative of the Office of Legal Counsel briefed the Members and Advisors on their roles and responsibilities and identified the mandate of the Committee under the relevant provisions of the IHR. 

    The Ethics Officer from the Department of Compliance, Risk Management, and Ethics proceeded with the rollcall and provided the Members and Advisors with an overview of the WHO Declaration of Interests process. 

    The Members and Advisors were made aware of their individual responsibility to disclose to WHO, in a timely manner, any interests of a personal, professional, financial, intellectual or commercial nature that may give rise to a perceived or actual conflict of interest. 

    They were additionally reminded of their duty to maintain the confidentiality of the meeting discussions and the work of the Committee. Each Member and Advisor was surveyed, with no conflicts of interest identified.

    The meeting was handed over to the Chair who introduced the objectives of the meeting, which were to provide views to the DG on whether the event continues to constitute a PHEIC, including a pandemic emergency, and to provide views on the proposed temporary recommendations.


Session open to representatives of States Parties invited to present their views

    Representatives of the DRC and Uganda updated the Committee on the BVD epidemiological situation in their countries, their current response efforts, needs and challenges. Ahead of the meeting, France submitted a written statement to the Committee regarding an imported BVD confirmed case from the DRC.

    The WHO Secretariat presented a comparative assessment of the indicators associated with each of the three criteria defining a PHEIC between 17 May 2026, when the PHEIC was determined, and 12 August 2026, as well as the indicators associated with each of the criteria defining a pandemic emergency, as per Article 1 - Definitions of the IHR. The WHO Secretariat also presented an overview of health operations and the scale up strategy in response to the BVD epidemic.

With respect to the indicators associated with the PHEIC criteria, the following assessment was presented.


1. Extraordinary

1.1. Growth rate (effective reproductive number (Rt))

    On 17 May 2026, the growth rate could not be calculated, though it was understood to be very high, given the orders-of-magnitude increase in the number of confirmed cases since then. Case-based estimates now suggest a doubling time of 52 days and an Rt of 1.24; however, low case ascertainment means these figures are likely to understate true transmission. Deaths are considered a more reliable indicator of epidemic growth, given higher relative ascertainment of fatal outcomes. Based on mortality data, the estimated doubling time is 21 days, with an Rt of 1.55. Triangulation across multiple methods and data sources further estimates that the true size of the epidemic is 3 to 4 times larger than what is reflected by surveillance data. Growth rate was assessed as ‘very high’ at the time the PHEIC was determined and continues to be assessed as ‘very high’ as of 12 August 2026, with confidence improving from ‘low’ to ‘moderate.’


1.2. Within country geographical spread (number of health zones with BVD in the DRC)

    On 17 May 2026, BDBV was known to be present in three health zones in the DRC. As of 12 August 2026, its presence had expanded to 55 health zones, 49 of which had active transmission. The geographic mapping of confirmed BVD cases likely understates the real extent of the spread, as some affected areas remain outside government control or are subject to insecurity limiting surveillance and response operations. Forecasting identifies 15 health zones at highest risk of further expansion in the coming week, four of which border Uganda, South Sudan, and Rwanda. The indicator increased from ‘moderate’ on 17 May 2026 to ‘high’ on 12 August 2026, with the level of confidence remaining ‘moderate’.


1.3. Challenges to contact tracing (proportion of BVD cases from listed contacts)

    Challenges with contact tracing persist unchanged. While the follow-up of listed contacts stands at approximately 80%, the average of 13 listed contacts per BVD case is far lower than that observed in previous viral hemorrhagic fever outbreaks. This results in only approximately 20% of BVD cases being identified through the follow up of listed contacts, and 40% of the BVD cases eventually linked to a chain of transmission. Challenges to contact tracing were assessed as ‘very high’ on 17 May 2026 and they remained ‘very high’ as of 12 August 2026. The level of confidence of those assessments moved from ‘low’ (17 May 2026) to ‘moderate’ (12 August 2026).


1.4. Severity (case fatality ratio (CFR))

    Early in the epidemic (around mid-May 2026), the crude CFR appeared as low as 20%, as the numerator did not include several deaths among persons under investigation for suspected BVD. As surveillance improved, as of 12 August 2026, the crude CFR stands at approximately 46%, notwithstanding persisting limitations in data quality. As expected, the CFR varies by age, with no meaningful difference observed by sex. The assessment of the severity as ‘high’ remained unchanged between 17 May and 12 August 2026, with the level of confidence moving from ‘low’ to ‘moderate.’


1.5. Disruption to health services (various)

    Before the BVD epidemic was detected, health services in the areas with current BVD transmission were already under strain from a deteriorating humanitarian situation, compounded by funding withdrawals, attacks on healthcare facilities, and supply chain disruptions. According to the most recent assessment conducted after the BVD epidemic was detected, the use of health care services has fallen by more than 40% in some of the areas with BVD transmission. Despite that, the observed incidence of malaria, cholera, and trauma cases remain high. In Ituri Province, maternal deaths have doubled since May 2026, currently averaging more than six per week. As of 17 May 2026, the disruption to health services was assessed as ‘moderate’ and, due to its worsening, it was assessed as ‘high’ as of 12 August 2026. Due to the scarcity of data, the level of confidence in those assessments remained ‘low’ and unchanged between 17 May 2026 and 12 August 2026.


2. International spread

2.1. Number of States Parties with BVD cases (imported cases, including resulting in limited local transmission)

    Historically, imported cases of Ebola virus infection have been reported during past outbreaks. However, only in a very limited number of instances have imported cases resulted in onwards transmission - limited to a very small number of cases – in States Parties outside Africa. In the context of the ongoing BVD epidemic in the DRC, modelled estimates indicate the risk of BVD spread to States Parties outside Africa remains very low. With respect to the risk of BVD spread from the DRC to other States Parties in Africa, modelled estimates indicate that this is significant for States Parties sharing land borders with provinces of the DRC with BVD transmission. Beside the possibility of reintroduction of BVD into Uganda, the risk is highest for South Sudan, reflecting its connectivity with the DRC. It is noted that the Central African Republic was not included at the time the modelled estimates were calculated.

    As of 17 May 2026, two States Parties (the DRC and Uganda) had detected BVD cases, with BVD cases in Uganda resulting from importations from the DRC and limited onwards local transmission. At that time the indicator was assessed as ‘low’. As of 12 August 2026, active BVD cases were reported only in the DRC, following control of BVD transmission in Uganda. The single imported BVD case detected in France did not result in onward transmission. The assessment of this indicator therefore remains ‘low’. Between 17 May and 12 August 2026, the level of confidence moved from ‘moderate’ to ‘high.’


2.2. Gaps in preparedness in States Parties sharing land borders with the DRC (and Uganda) (composite percentage)

    States Parties considered in this assessment are those sharing land borders with the DRC, as well as with Uganda, given the detection of imported BVD cases in Uganda early in the epidemic, and include Angola, Burundi, Central African Republic, Kenya, Republic of Congo, Rwanda, South Sudan, Tanzania and Zambia. In the context of quarterly readiness self-assessment, coordinated by the WHO Regional Office for Africa, a specific BVD-readiness assessment was conducted in the third quarter of 2026. The average readiness score of that assessment, encompassing 11 readiness domains and expressed in percentage, is as follows: Central African Republic - 38%; Republic of Congo - 50%; Tanzania - 53%; Angola - 64%; South Sudan - 65%; Zambia - 70%; Rwanda - 94%. There are no data available for Burundi and Kenya. The assessment of this indicator as ‘high’ remained unchanged between 17 May and 12 August 2026, with the level of confidence remaining ‘moderate’.


3. International cooperation

3.1. In-country response capacity exceeded (expert judgement based on operational outputs and epidemiological data)

    Since the BVD epidemic was detected in the DRC, the national response capacity has been scaled up. As of 12 August 2026, there were 21 laboratories with BDBV testing capacity, and approximately 1000 beds for the treatment of BVD cases. Although these figures may represent the fastest scale-up on record and reflect a very large-scale operational response, the late detection of the epidemic and the resulting unprecedented growth in BVD cases have outpaced the combined response capacity of the Government and partners. For example, the estimated number of beds needed for the treatment of BVD cases is 3000. Furthermore, there is a need to maintain essential health and humanitarian services amid severe access constraints, large-scale displacement and logistical disruptions, including the closure of the airports in Goma and Bukavu. The closure of these airports has hindered the delivery of essential supplies and led to recurrent stock-outs, further increasing the risk of morbidity and mortality. While this indicator was assessed as ‘high’ on 17 May 2026, in light of mounting humanitarian pressures, dwindling resources and the pace of epidemic growth, it was assessed as ‘very high’ on 12 August 2026, with the level of confidence remaining ‘high’.


3.2. Need for coordination of international response (expert judgement based on response operations data)

    Since the BVD epidemic was detected in May 2026, a continental preparedness and response plan was developed to support the implementation of national plans and coordinate the work of more than 30 named partners, with all partner response activities coordinated under a Continental Incident Management Support Team. Under that framework, a joint financial tracking mechanism has been established. As of 12 August 2026, there were 94 partners reporting engagement in the BVD response, across multiple technical pillars, with operations concentrated in Ituri, North Kivu and South Kivu Provinces in the DRC, leaving critical gaps in partner support elsewhere in the country. The WHO Secretariat has deployed 274 staff, including through partner networks, against a target of 455. The overall need for coordination of the international response was assessed as ‘high’ on 17 May 2026, and remained such as of 12 August 2026, with the level of confidence remaining unchanged as ‘high’.


3.3. Access to BVD-specific countermeasures

    As was the case when the BVD epidemic was detected in May 2026, as of 12 August 2026, no BVD-specific countermeasure is licensed. This indicator therefore remains not applicable.

    Members of, and Advisors to, the Committee then engaged in questions and answers with States Parties’ Representatives and the WHO Secretariat.


Deliberative session

    Following the session open to invited States Parties, the Committee reconvened in a closed session to examine the questions in relation to whether the event constitutes a PHEIC, including a pandemic emergency, and to consider the temporary recommendations drafted by the WHO Secretariat in accordance with IHR provisions.

    The Chair reminded the Committee Members of their mandate and recalled the definitions of PHEIC and pandemic emergency, as per Article 1 - Definitions of the IHR.

    Except for one Member, the Committee expressed the view that the BVD epidemic in the DRC continues to constitute a PHEIC but does not meet the criteria of a pandemic emergency, and that the DG be advised accordingly.

    The Committee subsequently considered the temporary recommendations to States Parties proposed by the WHO Secretariat.

    The Committee, ahead of its meeting, had received proposed temporary recommendations drafted by the WHO Secretariat in accordance with the provisions of the IHR, and subsequently offered its insightful advice.

    Specifically, the Committee called for the formulation of temporary recommendations stressing the urgency of immediately intensifying core interventions, including a drastic operational scale-up of human resources, as well as for planning efforts to sustain the response to the BVD epidemic over a prolonged period.


Conclusions

    The Executive Director of the WHO Health Emergency Preparedness and Response Programme, on behalf of the DG, expressed his gratitude to the Committee’s Officers, its Members and Advisors and closed the meeting.


===


Annex

    In accordance with paragraph 4.12, under Reports on Meetings of Committees in the WHO Regulations for Expert Advisory Panels and Committees, the Committee hereby records the divergent views expressed by one Member with respect to the “Statement by the Committee”.

    While the Statement reflects the deep concern expressed by the other Members of the Committee in the course of formulating their advice to the Director-General on whether the event constitutes a public health emergency of international concern, one Member indicated that the Statement extends beyond the terms of reference of the Committee, as set forth in Articles 12, 17, 48 and 49 of the IHR.

    The specific reasons provided by the Member relate to the following aspects addressed in the Statement: “operational management of the response, national response planning, resource allocation and mobilization, political or diplomatic engagement, or humanitarian and security arrangements.”

Source: 


Link: https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report

____

My New Space

Most Popular Posts